Molecular Imaging 2017

Re-irradiation of recurrent high grade gliomas. SFR, 30 Gy, 5Gy/f +TMZ : AA-PET/CT/MRI plan vs. CT/MRI plan

Significant survival advantage for the patients with recurrent gliomas treated with SFR based on AS-PET/SPECT/MRI/CT (median 9 mo,mean 14 mo) compared to the patients treated with SFR planned by anatomical imaging (CT/MRI) (median 5 mo, mean 6 mo), p = 0.031 (Grosu IJROBP 2005)

Survival curves for patients with recurrent gliomas treated with SFR based on biological imaging and temozolomide (median 11 months, mean 16 months) vs. patients treated with SFR without temozolomide, without biological imaging or without both components (median 6 months, mean 8 months), p=0.008 (Grosu IJROBP 2005)

1,2

1,2

1,0

1,0

,8

,8

,6

,6

PET or SPECT

Survival (%)

,4

PET/SPECT+Temoz

no

Survival (%)

,4

yes

,2

yes

,2

0,0

0

10

20

30

40

50

no

0,0

Months

0

10

20

30

40

50

Months